What Aktis Oncology does

Aktis Oncology is a clinical-stage biotechnology company founded in 2020 and headquartered in Boston, Massachusetts, with research operations in Research Triangle Park, North Carolina. The company is developing a proprietary class of targeted radiopharmaceuticals designed to address solid tumor types that have historically been beyond the reach of approved radiopharmaceutical therapies. Its integrated offering centers on a proprietary miniprotein radioconjugate platform that engineers custom tumor-targeting ligands paired with the alpha-emitting radioisotope actinium-225, exploiting the high cell-killing potency of alpha particles while sparing healthy tissue through rapid systemic clearance. Integrated theranostic imaging agents (e.g., Ga-68 labeled counterparts) enable visualization of tumor uptake to guide patient selection.

The company's clinical pipeline includes AKY-1189, a Nectin-4-targeted radioconjugate that received FDA Fast Track Designation for locally advanced or metastatic urothelial cancer and is currently in a multi-site U.S. Phase 1b study (NCT07020117) across urothelial, breast, NSCLC, colorectal, cervical, and head and neck cancers; AKY-2519, a B7-H3-targeted radioconjugate in a U.S. Phase 1b trial (NCT07581184) for metastatic castration-resistant prostate cancer with first-in-human data presented at ASCO 2026; undisclosed radioconjugate programs under a 2024 discovery collaboration with Eli Lilly; and additional discovery-stage programs. The company completed a $365.4 million IPO on Nasdaq in January 2026 under ticker AKTS, with pro forma cash of approximately $562.1 million expected to fund operations into 2029.

Aktis's business model is currently collaboration-driven rather than product-driven. Revenue is generated from the Eli Lilly strategic research partnership (which includes a $60 million upfront payment and potential milestone payments up to $1.1 billion), recording $4.6 million in revenue for the nine months ended September 30, 2025, against a $63.7 million net loss for FY2025. The company is pre-commercial with no approved products; future revenue is expected to derive from direct sales of approved radiopharmaceutical therapies in the U.S. and potential partner-driven commercialization in other geographies, supported by an in-house manufacturing and just-in-time supply chain capability being built out for short-shelf-life radiopharmaceuticals. Customer segments are dual: oncology patients with Nectin-4 or B7-H3 expressing solid tumors (urothelial, breast, NSCLC, colorectal, cervical, head and neck, mCRPC, lung) and large pharmaceutical companies seeking differentiated radiopharmaceutical platforms.

Name

Aktis Oncology

Legal name

Aktis Oncology, Inc.

Website

https://aktisoncology.com

Company type

Public

Founded year

2020

Operating status

Ipo

Headcount range

51–100 employees

Short description

Aktis Oncology is a clinical-stage biotechnology company developing proprietary miniprotein radioconjugate therapies that deliver actinium-225 alpha radiation to solid tumors expressing Nectin-4 or B7-H3, targeting patient populations beyond the reach of approved radiopharmaceuticals like Lutathera and Pluvicto.

Ownership category

akta.pro rank

Product category

Targeted Radiopharmaceuticals for Oncology

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Targeted radiopharmaceuticals
• Alpha-emitting therapeutics
• Miniprotein radioconjugates
• Cancer drug development
• Solid tumor therapeutics

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Collaboration & Licensing Revenue (Eli Lilly Partnership): Revenue generated from the strategic research collaboration with Eli Lilly, including an upfront payment of $60 million and potential milestone payments up to $1.1 billion in aggregate for novel radioconjugates developed using Aktis's miniprotein platform. Recorded $4.6 million in revenue for the nine months ended September 30, 2025.
2. Future Direct Product Sales (Planned): Currently pre-commercial clinical-stage company with no approved products; revenue model upon commercialization expected to rely on direct sales of approved radiopharmaceutical therapies for solid tumors in the U.S. and potentially partner-driven commercialization in other geographies.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

Aktis Oncology is a clinical-stage biotechnology company developing a new class of targeted alpha-emitting radiopharmaceuticals for solid tumors. Its proprietary miniprotein radioconjugate platform engineers tumor-targeting ligands that deliver actinium-225 (an alpha-emitter) payloads directly to cancer cells with deep tumor penetration, long residence times, and rapid systemic clearance. Lead clinical-stage candidates include AKY-1189 (Nectin-4, FDA Fast Track Designation for urothelial cancer) and AKY-2519 (B7-H3, Phase 1b for mCRPC), supported by a discovery collaboration with Eli Lilly and additional undisclosed programs.

Product overview

Aktis Oncology offers a single integrated offering centered on its proprietary miniprotein radioconjugate platform, which powers a pipeline of clinical-stage and discovery-stage targeted alpha-emitting radiopharmaceuticals for solid tumors. The platform generates product candidates — most notably the clinical-stage assets AKY-1189 (targeting Nectin-4 expressing tumors, with FDA Fast Track designation in urothelial cancer) and AKY-2519 (targeting B7-H3 expressing tumors such as mCRPC and lung cancer) — along with partnered programs under the existing discovery collaboration with Eli Lilly and additional multiple undisclosed discovery programs. Together, the platform, the named clinical assets, and the partnered/discovery programs constitute Aktis's portfolio for delivering actinium-225 payloads to tumor sites with high precision and limited normal tissue exposure.

Differentiator

Problem solved

Functional benefit

Products and services

• Miniprotein Radioconjugate Platform Aktis Oncology's proprietary discovery and development platform that generates custom-engineered targeted radiopharmaceuticals to deliver powerful alpha-emitting radioisotopes (actinium-225) directly to tumors. The platform enables precision targeting with deep tumor penetration, long residence times, and rapid clearance from normal tissues, and supports a theranostic approach to visualize and verify tumor target engagement.
• AKY-1189 A miniprotein radioconjugate designed to deliver actinium-225 to Nectin-4 expressing solid tumors. Granted FDA Fast Track Designation for locally advanced or metastatic urothelial cancer (mUC) in patients who have progressed on or after prior systemic therapies. Currently in a multi-site U.S. Phase 1b study (NCT07020117, NECTINIUM-2) for mUC, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer.
• AKY-2519 A miniprotein radioconjugate designed to deliver actinium-225 to B7-H3 expressing tumors. Currently in a multi-site U.S. Phase 1b trial (NCT07581184) for metastatic castration-resistant prostate cancer (mCRPC). A second Phase 1b basket trial in lung, colorectal, and other B7-H3 expressing solid tumors is planned for H2 2026. First-in-human imaging and dosimetry data presented at ASCO 2026.
• Aktis-Lilly Discovery Collaboration Programs Undisclosed targets under an existing discovery collaboration with Eli Lilly to develop novel radioconjugates using Aktis's miniprotein platform, for which Aktis received a $60 million upfront payment as part of a broader partnership valued at up to $1.1 billion in potential milestones.

Quantifiable outcome

• Eli Lilly committed up to $1.1 billion in potential milestones plus $60M upfront payment under strategic research partnership
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 1 January 2024Eli Lilly partnered with Aktis Oncology to develop novel tumor-targeting radiopharmaceuticals using Aktis's miniprotein platform. The deal included a $60 million upfront payment to Aktis and up to $1.1 billion in potential milestone payments. Lilly also served as anchor investor in Aktis's January 2026 IPO, purchasing approximately $100 million of shares at the IPO price, validating the platform. The discovery collaboration targets undisclosed radioconjugate programs.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Bayer (Xofigo / Algeta legacy):
• Lantheus Holdings: Lantheus is a leading radiopharmaceutical company with commercial products (e.g., PYLARIFY, Definity) and a broad pipeline in oncology and diagnostics. As a broad incumbent in the targeted radiopharma space, it competes with Aktis for share-of-mind in solid-tumor imaging and therapy, though its portfolio is more diversified.
• Novartis (AAA / Pluvicto / Lutathera): Novartis owns Advanced Accelerator Applications (AAA) and the Pluvicto/Lutathera franchises, the dominant approved radiopharmaceutical therapies. As a broad incumbent, it competes head-on with Aktis's solid-tumor ambitions and already has a leading radioligand commercial infrastructure.

Direct peers

• Telix Pharmaceuticals: Telix is a commercial-stage radiopharma company marketing Illuccix (PSMA-PET imaging) and developing therapeutic radiopharmaceuticals across prostate cancer and other solid tumors. It is a direct peer to Aktis in the targeted radiopharmaceutical oncology space, with overlapping targets and clinical ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aktis-oncology

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aktis Oncology